The global kidney cancer drugs market size was USD 6.51 billion in 2023, estimated at USD 6.86 billion in 2024 and is anticipated to reach around USD 11.60 billion by 2034, expanding at a CAGR of 5.39% from 2024 to 2034.
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
3.1. Market Snapshot
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
5.1. COVID-19 Landscape: Kidney Cancer Drugs Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
8.1. Kidney Cancer Drugs Market Revenue and Volume, by Therapy Type, 2024-2034
8.1.1 Targeted Therapy
8.1.1.1. Market Revenue and Volume Forecast (2021-2034)
8.1.2. Immunotherapy
8.1.2.1. Market Revenue and Volume Forecast (2021-2034)
8.1.3. Chemotherapy
8.1.3.1. Market Revenue and Volume Forecast (2021-2034)
9.1. Kidney Cancer Drugs Market Revenue and Volume, by Pharmacological Class Type, 2024-2034
9.1.1. Angiogenesis Inhibitors
9.1.1.1. Market Revenue and Volume Forecast (2021-2034)
9.1.2. mTOR Inhibitors
9.1.2.1. Market Revenue and Volume Forecast (2021-2034)
9.1.3. Cytokinesis
9.1.3.1. Market Revenue and Volume Forecast (2021-2034)
9.1.4. Others (Immune Checkpoint Inhibitors, CTLA-4 Inhibitors, Antimetabolites, and Others)
9.1.4.1. Market Revenue and Volume Forecast (2021-2034)
10.1. Kidney Cancer Drugs Market Revenue and Volume, by Distribution Channel, 2024-2034
10.1.1. Hospital Pharmacies
10.1.1.1. Market Revenue and Volume Forecast (2021-2034)
10.1.2. Retail Pharmacies
10.1.2.1. Market Revenue and Volume Forecast (2021-2034)
10.1.3. Online Pharmacies
10.1.3.1. Market Revenue and Volume Forecast (2021-2034)
11.1. North America
11.1.1. Market Revenue and Volume Forecast, by Therapy Type (2021-2034)
11.1.2. Market Revenue and Volume Forecast, by Pharmacological Class Type (2021-2034)
11.1.3. Market Revenue and Volume Forecast, by Distribution Channel (2021-2034)
11.1.4. U.S.
11.1.4.1. Market Revenue and Volume Forecast, by Therapy Type (2021-2034)
11.1.4.2. Market Revenue and Volume Forecast, by Pharmacological Class Type (2021-2034)
11.1.4.3. Market Revenue and Volume Forecast, by Distribution Channel (2021-2034)
11.1.5. Rest of North America
11.1.5.1. Market Revenue and Volume Forecast, by Therapy Type (2021-2034)
11.1.5.2. Market Revenue and Volume Forecast, by Pharmacological Class Type (2021-2034)
11.1.5.3. Market Revenue and Volume Forecast, by Distribution Channel (2021-2034)
11.2. Europe
11.2.1. Market Revenue and Volume Forecast, by Therapy Type (2021-2034)
11.2.2. Market Revenue and Volume Forecast, by Pharmacological Class Type (2021-2034)
11.2.3. Market Revenue and Volume Forecast, by Distribution Channel (2021-2034)
11.2.4. UK
11.2.4.1. Market Revenue and Volume Forecast, by Therapy Type (2021-2034)
11.2.4.2. Market Revenue and Volume Forecast, by Pharmacological Class Type (2021-2034)
11.2.4.3. Market Revenue and Volume Forecast, by Distribution Channel (2021-2034)
11.2.5. Germany
11.2.5.1. Market Revenue and Volume Forecast, by Therapy Type (2021-2034)
11.2.5.2. Market Revenue and Volume Forecast, by Pharmacological Class Type (2021-2034)
11.2.5.3. Market Revenue and Volume Forecast, by Distribution Channel (2021-2034)
11.2.6. France
11.2.6.1. Market Revenue and Volume Forecast, by Therapy Type (2021-2034)
11.2.6.2. Market Revenue and Volume Forecast, by Pharmacological Class Type (2021-2034)
11.2.6.3. Market Revenue and Volume Forecast, by Distribution Channel (2021-2034)
11.2.7. Rest of Europe
11.2.7.1. Market Revenue and Volume Forecast, by Therapy Type (2021-2034)
11.2.7.2. Market Revenue and Volume Forecast, by Pharmacological Class Type (2021-2034)
11.2.7.3. Market Revenue and Volume Forecast, by Distribution Channel (2021-2034)
11.3. APAC
11.3.1. Market Revenue and Volume Forecast, by Therapy Type (2021-2034)
11.3.2. Market Revenue and Volume Forecast, by Pharmacological Class Type (2021-2034)
11.3.3. Market Revenue and Volume Forecast, by Distribution Channel (2021-2034)
11.3.4. India
11.3.4.1. Market Revenue and Volume Forecast, by Therapy Type (2021-2034)
11.3.4.2. Market Revenue and Volume Forecast, by Pharmacological Class Type (2021-2034)
11.3.4.3. Market Revenue and Volume Forecast, by Distribution Channel (2021-2034)
11.3.5. China
11.3.5.1. Market Revenue and Volume Forecast, by Therapy Type (2021-2034)
11.3.5.2. Market Revenue and Volume Forecast, by Pharmacological Class Type (2021-2034)
11.3.5.3. Market Revenue and Volume Forecast, by Distribution Channel (2021-2034)
11.3.6. Japan
11.3.6.1. Market Revenue and Volume Forecast, by Therapy Type (2021-2034)
11.3.6.2. Market Revenue and Volume Forecast, by Pharmacological Class Type (2021-2034)
11.3.6.3. Market Revenue and Volume Forecast, by Distribution Channel (2021-2034)
11.3.7. Rest of APAC
11.3.7.1. Market Revenue and Volume Forecast, by Therapy Type (2021-2034)
11.3.7.2. Market Revenue and Volume Forecast, by Pharmacological Class Type (2021-2034)
11.3.7.3. Market Revenue and Volume Forecast, by Distribution Channel (2021-2034)
11.4. MEA
11.4.1. Market Revenue and Volume Forecast, by Therapy Type (2021-2034)
11.4.2. Market Revenue and Volume Forecast, by Pharmacological Class Type (2021-2034)
11.4.3. Market Revenue and Volume Forecast, by Distribution Channel (2021-2034)
11.4.4. GCC
11.4.4.1. Market Revenue and Volume Forecast, by Therapy Type (2021-2034)
11.4.4.2. Market Revenue and Volume Forecast, by Pharmacological Class Type (2021-2034)
11.4.4.3. Market Revenue and Volume Forecast, by Distribution Channel (2021-2034)
11.4.5. North Africa
11.4.5.1. Market Revenue and Volume Forecast, by Therapy Type (2021-2034)
11.4.5.2. Market Revenue and Volume Forecast, by Pharmacological Class Type (2021-2034)
11.4.5.3. Market Revenue and Volume Forecast, by Distribution Channel (2021-2034)
11.4.6. South Africa
11.4.6.1. Market Revenue and Volume Forecast, by Therapy Type (2021-2034)
11.4.6.2. Market Revenue and Volume Forecast, by Pharmacological Class Type (2021-2034)
11.4.6.3. Market Revenue and Volume Forecast, by Distribution Channel (2021-2034)
11.4.7. Rest of MEA
11.4.7.1. Market Revenue and Volume Forecast, by Therapy Type (2021-2034)
11.4.7.2. Market Revenue and Volume Forecast, by Pharmacological Class Type (2021-2034)
11.4.7.3. Market Revenue and Volume Forecast, by Distribution Channel (2021-2034)
11.5. Latin America
11.5.1. Market Revenue and Volume Forecast, by Therapy Type (2021-2034)
11.5.2. Market Revenue and Volume Forecast, by Pharmacological Class Type (2021-2034)
11.5.3. Market Revenue and Volume Forecast, by Distribution Channel (2021-2034)
11.5.4. Brazil
11.5.4.1. Market Revenue and Volume Forecast, by Therapy Type (2021-2034)
11.5.4.2. Market Revenue and Volume Forecast, by Pharmacological Class Type (2021-2034)
11.5.4.3. Market Revenue and Volume Forecast, by Distribution Channel (2021-2034)
11.5.5. Rest of LATAM
11.5.5.1. Market Revenue and Volume Forecast, by Therapy Type (2021-2034)
11.5.5.2. Market Revenue and Volume Forecast, by Pharmacological Class Type (2021-2034)
11.5.5.3. Market Revenue and Volume Forecast, by Distribution Channel (2021-2034)
12.1. Abbvie
12.1.1. Company Overview
12.1.2. Product Offerings
12.1.3. Financial Performance
12.1.4. Recent Initiatives
12.2. Arlak Biotech
12.2.1. Company Overview
12.2.2. Product Offerings
12.2.3. Financial Performance
12.2.4. Recent Initiatives
12.3. Apikos Pharma
12.3.1. Company Overview
12.3.2. Product Offerings
12.3.3. Financial Performance
12.3.4. Recent Initiatives
12.4. Astellas Pharma
12.4.1. Company Overview
12.4.2. Product Offerings
12.4.3. Financial Performance
12.4.4. Recent Initiatives
12.5. AstraZeneca plc
12.5.1. Company Overview
12.5.2. Product Offerings
12.5.3. Financial Performance
12.5.4. Recent Initiatives
12.6. Amgen Inc
12.6.1. Company Overview
12.6.2. Product Offerings
12.6.3. Financial Performance
12.6.4. Recent Initiatives
12.7. Allena Pharmaceuticals
12.7.1. Company Overview
12.7.2. Product Offerings
12.7.3. Financial Performance
12.7.4. Recent Initiatives
12.8. AVEO Oncology
12.8.1. Company Overview
12.8.2. Product Offerings
12.8.3. Financial Performance
12.8.4. Recent Initiatives
12.9. AID Genomics Limited
12.9.1. Company Overview
12.9.2. Product Offerings
12.9.3. Financial Performance
12.9.4. Recent Initiatives
12.10. AQVIDA GmbH
12.10.1. Company Overview
12.10.2. Product Offerings
12.10.3. Financial Performance
12.10.4. Recent Initiatives
13.1. Primary Research
13.2. Secondary Research
13.3. Assumptions
14.1. About Us
14.2. Glossary of Terms
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
Report Description
Get a Sample